RecruitingNCT06178822

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

Sponsor

Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)

Enrollment

3,300 participants

Start Date

Oct 25, 2022

Study Type

OBSERVATIONAL

Conditions

Sepsis Infections Septic Shock Infection, Bacterial Sepsis, Severe Infection Viral Infections, Respiratory

Summary

Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Age 18 years or higher
Presentation at the Emergency Department (ED)
Clinical suspicion of infection or earlier confirmed infection
Modified Early Warning Score (MEWS) of 2 or higher

Exclusion Criteria1

No informed consent given

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

There is no intervention

Locations(3)

Flevoziekenhuis

Almere Stad, Flevoland, Netherlands

Amsterdam UMC, location VUMC

Amsterdam, North Holland, Netherlands

Amsterdam UMC, location AMC

Amsterdam, North Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06178822

Related Trials

Febrile Infants Swedish Study

NCT0713475111 locations

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock

NCT0717927623 locations